載入中
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
前收盤價
US$13.065
+US$0.375 · +2.96%
盤中時間採用ET。市場資料可能有所延遲。
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
日內區間
目前US$13.065
52週區間
目前US$13.065
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5.68億 USD | 5.73億 USD | 5.12億 USD | 5.12億 USD | 4.31億 USD |
| 銷貨成本 | 1.86億 USD | 1.85億 USD | 1.84億 USD | 1.81億 USD | 1.28億 USD |
| 毛利 | 3.82億 USD | 3.88億 USD | 3.28億 USD | 3.31億 USD | 3.03億 USD |
| 研究與開發 | 1211.3萬 USD | 1363.9萬 USD | 1344.6萬 USD | 2385.4萬 USD | 1903.9萬 USD |
| 銷售、一般及管理費用 | 3.12億 USD | 3.27億 USD | 3.04億 USD | 3.32億 USD | 2.54億 USD |
| 營業費用 | 3.24億 USD | 4億 USD | 4.1億 USD | 4.98億 USD | 2.91億 USD |
| 利息支出 | 2648.6萬 USD | 3879.2萬 USD | 4067.6萬 USD | 1202.1萬 USD | 111.2萬 USD |
| 折舊和攤銷 | 4701.1萬 USD | 4955.5萬 USD | 5736.5萬 USD | 5539.8萬 USD | 3487.5萬 USD |
| 營業利益 | 5854.7萬 USD | −1197.9萬 USD | −8172.5萬 USD | −1.67億 USD | 1206.1萬 USD |
| 淨利 | 2273.2萬 USD | −3354.2萬 USD | −1.56億 USD | −1.59億 USD | 1937.5萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$18.33
上漲空間 40.30%報告持有此股票曝險的交易所交易基金。
Avantis U.S. Small Cap Value ETFAVUV2274.33萬0.07%308.51億 USD0.25%US$119.64-0.41%
iShares Russell 2000 ETFIWM1611.4萬0.02%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI1588.42萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF743.35萬0.01%954億 USD0.05%US$235+0.80%
Dimensional - US Small Cap ETFDFAS565.71萬0.02%338.69億 USD0.31%US$78.35+0.32%
iShares Russell 2000 Growth ETFIWO558.65萬0.04%139.17億 USD0.24%US$356.78+0.94%
Fidelity Enhanced Small Cap ETFFESM406.13萬0.06%64.1億 USD0.28%US$45.46+0.46%
Vanguard Russell 2000 ETFVTWO377.88萬0.02%180億 USD0.06%US$112.66+0.50%Avantis U.S. Small Cap Value ETFAVUViShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Russell 2000 Growth ETFIWOFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
